Haemonetics vs Integra LifeSciences
HAE and IART side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HAE and IART compare
Haemonetics is the larger company, worth 5.0 times as much as Integra LifeSciences ($5.6B against $1.1B).
On earnings, Haemonetics is cheaper: it trades at 54.9× trailing earnings, against 84.7× for Integra LifeSciences.
Haemonetics grew revenue faster over the last twelve months (4.1% versus 0.84% for Integra LifeSciences).
Haemonetics keeps more of each dollar of sales as profit, with a net margin of 7.5% compared with 0.79% at Integra LifeSciences.
Integra LifeSciences scores higher on the StockData Score (9 against 7 for Haemonetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HAE | IART |
|---|---|---|
| Size and price | ||
| Market cap | $5.6B | $1.1B |
| Share price | $122.94 | $14.40 |
| Change, 1 year | 68.1% | 19.1% |
| Change, 5 years | 119% | −79.1% |
| Beta (5Y) | 0.64 | 1.25 |
| Employees | – | 3,700 |
| StockData Score | ||
| Total score | 7 | 9 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 3 | 3 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 54.9× (better) | 84.7× |
| P/S | 4.0× | 0.7× (better) |
| P/B | 6.2× | 1.1× (better) |
| EV/EBITDA | 22.5× | 11.1× (better) |
| P/FCF | 18.8× | 13.1× (better) |
| FCF yield | 5.3% | 7.7% (better) |
| Fair value | $75.19 | $14.86 |
| Margin of safety | −63.5% | 3.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 4.1% (better) | 0.84% |
| Revenue growth, 5Y average | 8.9% (better) | 3.6% |
| Net income growth (TTM) | −38.2% | – |
| EPS growth (TTM) | −34.5% | – |
| EPS growth, 5Y average | 5.8% | – |
| Profitability | ||
| Gross margin | 59.6% (better) | 52.4% |
| Operating margin | 12.8% (better) | 4.4% |
| Net margin | 7.5% (better) | 0.79% |
| FCF margin | 21.6% (better) | 5.2% |
| Return on equity | 11.9% (better) | 1.2% |
| Return on invested capital | 7.3% (better) | 5.6% |
| Financial health | ||
| Debt / equity | 1.25 | – |
| Net debt / EBITDA | 3.01 | – |
| Interest coverage | – | 0.8× |
| Current ratio | 2.84 | 3.62 (better) |
| Altman Z-score | 3.52 (better) | 1.29 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 109% | 94.4% |
| Held by insiders | 1.8% | 3.4% |
| Insider net buying, 12 months | $0 | $0 |
| Short interest, % of float | 8.1% | 10.5% |
Go deeper
- HAE stock overview
- HAE income statement
- HAE valuation and score
- IART stock overview
- IART income statement
- IART valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.